Navigation Links
Homogeneous tuberculosis treatment ineffective in children, UT Southwestern researchers find
Date:2/10/2011

DALLAS Feb. 10, 2011 The realization of medically treating different children uniquely may start with one of the deadliest diseases in existence: tuberculosis.

New findings by UT Southwestern Medical Center researchers indicate that the type of medications and the dosage routinely used to treat children with the disease should be individualized to each young patient in order to be effective.

The findings, available online and in the February issue of Antimicrobial Agents and Chemotherapy, show that currently recommended doses are much too low and that a child's weight, age and medical history are among a myriad of factors that can affect his or her response to a particular drug used to combat the Mycobacterium tuberculosis bacterium, which causes the disease.

"Children are growing and changing and, unlike in adults, Mycobacterium tuberculosis manifests itself in children as many different diseases, causing problems all over the body," said Dr. Tawanda Gumbo, associate professor of internal medicine at UT Southwestern and the study's lead author. "Since their immune systems are not yet fully developed, you also have to take into consideration whether a particular drug will reach the part of the body affected by the disease.

"If you aggregate all these factors age, weight, medical history, disease process it's pretty clear that you need to treat each child differently instead of following the standard dosing guidelines."

About one-third of the world's population is infected with Mycobacterium tuberculosis and 2 million people die from the disease each year. TB, the leading cause of death among people infected with HIV/AIDS, kills more people than any other disease caused by a single infectious agent, according to the National Institutes of Health. Treatment usually lasts six to 12 months and includes a combination of drugs administered simultaneously, in hopes of preventing drug resistance.

For the study, the researchers virtually simulated clinical trials involving 10,000 patients who are 10 years old or younger. The computer simulation factored in pharmacokinetics (how a body handles a drug based on heterogeneous factors) to determine how likely a dose of a given drug is to kill TB. The children were grouped into three groups: fast acetylators, meaning their bodies metabolize the drugs quickly; children ages 1 to 10 who are slow acetylators; and infants who are slow acetylators.

Dr. Gumbo's team found that the drug concentrations typically used to treat children with TB are too low and that children respond differently to the standardized medication depending partly on their age and how quickly their bodies metabolize the drug.

"Despite the desire for standardized therapy, our findings support the long-held notion that there is no 'average' or 'standard' child. It is safe to assume that with 2.2 billion children worldwide, there will be 2.2 billion different regimens needed to effectively treat tuberculosis," Dr. Gumbo said.

He said the importance of the findings is that they can be applied to many other infections, including methicillin-resistant-Staphylococcus aureus, or MRSA.

"This is the future, even for adults," Dr. Gumbo said. "Being able to individualize what drug someone gets and what dose this is the future of medicine."

Dr. Gumbo's research is funded by a 2007 NIH Director's New Innovator Award, which supports bold ideas from some of the nation's most innovative early-career scientists.

Dr. Jotam Pasipanodya, research scientist in internal medicine at UT Southwestern, and researchers from the University of KwaZulu-Natal, the Howard Hughes Medical Institute, and the Kwa-Zulu Natal Research Institute for Tuberculosis and HIV in South Africa also contributed to the study.


'/>"/>

Contact: Kristen Holland Shear
kristen.hollandshear@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Older people and those with HIV are more vulnerable to tuberculosis
2. UN Foundation President Timothy E. Wirth Commends African Leaders for Renewed Commitment to the Global Fund to Fight AIDS, Tuberculosis and Malaria
3. Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection
4. A breakthrough in tuberculosis research
5. A*STAR and Institut Merieux/bioMerieux invest S$3m ($2.2m) in tuberculosis research
6. New genomic marker for tuberculosis may help identify patients who will develop the disease
7. New dual recognition mechanism discovered in tuberculosis
8. Einstein scientist awarded $4 million to develop genetic strategy to combat tuberculosis
9. Study finds evidence of increased lung cancer risk among tuberculosis patients
10. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
11. Women More Likely to Fail Treatment for Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Today, ... Biscom Document Router (BDR), the first IoT device from Biscom designed to deliver ... Biscom will debut BDR at HIMSS17 and will be conducting demonstrations ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's Hospital celebrated ... topping out ceremony on Friday marked the halfway point of construction and lifting of ... Fall 2018, will serve as a center for innovation aimed at finding new discoveries ...
(Date:2/19/2017)... ... 19, 2017 , ... Braun Industries will be participating as an exhibitor at ... take place February 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center ... new ambulances on display. , “JEMS is a leader in EMS ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused ... innovation in the industry, according to the recent NEJM Catalyst Insights Report on ... of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical ...
(Date:2/18/2017)... La. (PRWEB) , ... February 18, 2017 , ... ... released today provides the latest information and contact points to easily connect elderly ... home care, assisted living, and elder-care funding. It also conveys material on this ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... YORK, Feb. 20, 2017 Report analyzes ... by the following Product Segments: Ambulatory Infusion Pumps, ... Infusion Pumps, PCA Infusion Pumps, and Syringe Infusion ... the US, Canada, Japan, Europe, Asia-Pacific, Latin America, ... full report: http://www.reportlinker.com/p04707120-summary/view-report.html Annual estimates ...
(Date:2/20/2017)... This report analyzes the worldwide markets for Human ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Rest of World. ... Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
(Date:2/20/2017)... 2017 The Global PSA Oxygen Concentrators ... a comprehensive analysis of the PSA Oxygen Concentrators market. From ... classification, application, and industry chain overview are all covered in ... SWOT analysis, and investment return analysis of the PSA Oxygen ... ...
Breaking Medicine Technology: